肝细胞癌分子分型与精准肿瘤学进展
本综述总结肝细胞癌(HCC)分子生物学主要进展,指出HCC由多个基因组和表观基因组改变经达尔文选择序贯积累所致,涉及端粒维持、Wnt/β-catenin、P53/细胞周期调控、氧化应激、表观遗传修饰、AKT/mTOR和MAP激酶等信号通路基因频繁突变,并讨论基于转录组失调和遗传改变识别的亚类与风险因素、病理特征及预后相关,以及整合临床前模型和人类研究数据加速靶向与免疫治疗反应预测生物标志物识别的前景。
要点
- HCC发生源于多个基因组和表观基因组改变的序贯积累与达尔文选择。
- 端粒维持、Wnt/β-catenin、P53/细胞周期、氧化应激、表观遗传、AKT/mTOR和MAPK通路基因在HCC中频繁突变。
- 基于转录组失调和遗传改变可识别与风险因素、病理特征和预后相关的HCC亚类。
核心结论
- HCC分子分型基于转录组失调和遗传改变,与风险因素、病理特征和预后密切相关。
- 整合临床前模型和人类研究数据可加速识别靶向治疗和免疫治疗反应的稳健预测生物标志物。
研究设计与样本
- 综述类文章,描述HCC分子生物学主要进展并讨论未来临床应用。
主要发现
- HCC由肝细胞经多个基因组和表观基因组改变的序贯积累及达尔文选择发生。
- 端粒维持、Wnt/β-catenin、P53/细胞周期调控、氧化应激、表观遗传修饰、AKT/mTOR和MAP激酶等通路基因在HCC中频繁突变。
- 已识别多个基于转录组失调和遗传改变的HCC亚类,与风险因素、病理特征和预后密切相关。
临床怎么用
- 未来可将HCC分子生物学知识用于临床实践,辅助靶向治疗和免疫治疗反应预测生物标志物的识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) arises from hepatocytes through the sequential accumulation of multiple genomic and epigenomic alterations resulting from Darwinian selection. Genes from various signalling pathways such as telomere maintenance, Wnt/β-catenin, P53/cell cycle regulation, oxidative stress, epigenetic modifiers, AKT/mTOR and MAP kinase are frequently mutated in HCC. Several subclasses of HCC have been identified based on transcriptomic dysregulation and genetic alterations that are closely related to risk factors, pathological features and prognosis. Undoubtedly, integration of data obtained from both preclinical models and human studies can help to accelerate the identification of robust predictive biomarkers of response to targeted biotherapy and immunotherapy. The aim of this review is to describe the main advances in HCC in terms of molecular biology and to discuss how this knowledge could be used in clinical practice in the future.
引用
- Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020. PMID: 31954487. doi:10.1016/j.jhep.2019.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。